PRIMARY STUDY
Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox
Key Findings: The authors posit that blockers of CB1 may represent a novel therapeutic agents in the treatment of CKD.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): France
Year of Pub: 2021
Cannabinoids Studied: Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1
Citation: Dao M and François H. Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox. Front Endocrinol (Lausanne). 2021; 12:720734. doi: 10.3389/fendo.2021.720734
Authors: Dao M, François H
